These medications can be prescribed by a licensed clinicianobesity specialist, general practitioner (MD, DO), endocrinologist, nurse practitioner, or physician assistantwhether in person or online
Kokkola, A
In addition to the US FDA approved GLP-1RAs, there are GLP1/glucagon dual agonists (Cotadutide, BI 456906), GIP/GLP1 dual agonists (Tirzepatide, GIP/GLP peptide I and II), GIP/GLP1/glucagon tri-agonists (HM15211, GGG tri-agonist) and GLP1R agonists (Efpeglenatide, Rybelsus) currently in phase 1- III clinical trials for T2D, obesity, and NASH (MASH) treatments (12)
Flexible Dosing: With options for both subcutaneous and oral administration, Semaglutide provides flexibility that caters to patient preferences and compliance, a notable advantage over other GLP-1 receptor agonists that are limited to subcutaneous delivery